| Market Cap | 17.76M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.25M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 15.00% |
| Sales | 42.02k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 24.00% |
| Dividend | N/A | Price/Book | 4.60 | EPS next 5Y | - | 52W High Chg | -38.00% |
| Recommedations | - | Quick Ratio | 26.34 | Shares Outstanding | 1.69B | 52W Low Chg | 130.00% |
| Insider Own | 40.61% | ROA | -27.02% | Shares Float | 1.05B | Beta | 0.74 |
| Inst Own | - | ROE | -70.91% | Shares Shorted/Prior | -/- | Price | 0.01 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 2,038 | Target Price | - |
| Oper. Margin | -3,536.68% | Earnings Date | - | Volume | 20,000 | Change | 0.00% |
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
